It plans to launch an online registry for patients interested in joining the process
Synchron , a rival to Musk's Neuralink , readies large-scale brain implant trialThe company aims to include patients who are paralyzed due to the neurodegenerative disease ALS , stroke and multiple sclerosis WASHINGTON – Synchron Inc, a rival to Elon Musk 's Neuralink brain implant startup, is preparing to recruit patients for a large-scale clinical trial required to seek commercial approval for its device, the company's chief executive told Reuters.
Synchron received US authorization for preliminary testing in July 2021 and has implanted its device in six patients. Prior testing in four patients in Australia showed no serious adverse side effects, the company has reported. Dr David Lacomis, chief of UPMC's Neuromuscular Division, said his team is still participating in the preliminary human testing “and the study is going well.”
Synchron's device is delivered to the brain via the large vein that sits next to the motor cortex in the brain instead of being surgically implanted into the brain cortex like Neuralink's.
Neuralink Elon Musk Brain Implant Trial Brain Computer Interface BCI BCI Devices Stroke Patients Neurodegenerative Disease ALS Amyotrophic Lateral Sclerosis Stroke Multiple Sclerosis
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
What are the foods for healthy brain and long life?Food scientists and nutritionists shares the secret of long life and brain health
Baca lebih lajut »
Merck to test single-dose regimen of HPV vaccine Gardasil 9The large, multi-year trials are expected to start enrolment in the fourth quarter of 2024
Baca lebih lajut »
Big hotel chains and unbranded-hotel owners find they need each otherLarge operators have launched
Baca lebih lajut »
SpaceX applies for Indonesia internet service provider permit, government saysElon Musk' company SpaceX provides the satellite internet service
Baca lebih lajut »
Japan shares scale record high, yen rebounds as Fed out-doves BOJThe BOJ sees room for another hike this year, with market viewing July or October as potential dates
Baca lebih lajut »
A new strategy to attack aggressive brain cancer shrank tumours in two early testsSo-called CAR-T therapy already is used to fight blood-related cancers like leukaemia
Baca lebih lajut »